GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
Abstract New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mo...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-023-02397-3 |
| _version_ | 1827979399859798016 |
|---|---|
| author | Viktoria Zaderer Stefanie Dichtl Wilfried Posch Ivane Abiatari Günther K. Bonn Thomas Jakschitz Lukas A. Huber Teymuras V. Kurzchalia Doris Wilflingseder |
| author_facet | Viktoria Zaderer Stefanie Dichtl Wilfried Posch Ivane Abiatari Günther K. Bonn Thomas Jakschitz Lukas A. Huber Teymuras V. Kurzchalia Doris Wilflingseder |
| author_sort | Viktoria Zaderer |
| collection | DOAJ |
| description | Abstract New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. |
| first_indexed | 2024-04-09T21:37:14Z |
| format | Article |
| id | doaj.art-c787dd554a134807a5ca1acee23c0174 |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-04-09T21:37:14Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-c787dd554a134807a5ca1acee23c01742023-03-26T11:16:22ZengBMCRespiratory Research1465-993X2023-03-012411910.1186/s12931-023-02397-3GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory eventsViktoria Zaderer0Stefanie Dichtl1Wilfried Posch2Ivane Abiatari3Günther K. Bonn4Thomas Jakschitz5Lukas A. Huber6Teymuras V. Kurzchalia7Doris Wilflingseder8Institute of Hygiene and Medical Microbiology, Medical University of InnsbruckInstitute of Hygiene and Medical Microbiology, Medical University of InnsbruckInstitute of Hygiene and Medical Microbiology, Medical University of InnsbruckSchool of Natural Sciences and Medicine Tbilisi, Ilia State UniversityAustrian Drug Screening Institute (ADSI)Austrian Drug Screening Institute (ADSI)Austrian Drug Screening Institute (ADSI)Dzala LLCInstitute of Hygiene and Medical Microbiology, Medical University of InnsbruckAbstract New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose.https://doi.org/10.1186/s12931-023-02397-3SARS-CoV-2ProphylaxisVariants of concernAntiviralTransmission |
| spellingShingle | Viktoria Zaderer Stefanie Dichtl Wilfried Posch Ivane Abiatari Günther K. Bonn Thomas Jakschitz Lukas A. Huber Teymuras V. Kurzchalia Doris Wilflingseder GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events Respiratory Research SARS-CoV-2 Prophylaxis Variants of concern Antiviral Transmission |
| title | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
| title_full | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
| title_fullStr | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
| title_full_unstemmed | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
| title_short | GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events |
| title_sort | glypera™ effectively shields airway epithelia from sars cov 2 infection and inflammatory events |
| topic | SARS-CoV-2 Prophylaxis Variants of concern Antiviral Transmission |
| url | https://doi.org/10.1186/s12931-023-02397-3 |
| work_keys_str_mv | AT viktoriazaderer glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT stefaniedichtl glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT wilfriedposch glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT ivaneabiatari glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT guntherkbonn glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT thomasjakschitz glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT lukasahuber glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT teymurasvkurzchalia glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents AT doriswilflingseder glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents |